**EXHIBIT        10.3**

**PATENT        AND TECHNOLOGY LICENSE AGREEMENT**

**(as        Amended)**

**RECITALS**

| A.   | BOARD                owns certain PATENT RIGHTS and TECHNOLOGY RIGHTS related to LICENSED                SUBJECT MATTER, which were jointly developed by LICENSEE and                MDA. |
|----------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| B.   | BOARD                desires to have the LICENSED SUBJECT MATTER developed in the LICENSED                FIELD and used for the benefit of LICENSEE, BOARD, SYSTEM, MDA, the                inventor(s), and the public as outlined in BOARD'S Intellectual Property                Policy. |
|----------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| C.   | LICENSEE                wishes to obtain an exclusive license from BOARD to its rights in                the                LICENSED SUBJECT MATTER, |
|----------------|------------------------------------------------------------------------------------------------------------------------------------------------------|

**NOW,        THEREFORE, in consideration of the mutual covenants and promises herein        contained, the parties agree as follows:**

**I.**
**EFFECTIVE        DATE**

| **1.1** | This                  AGREEMENT is effective as of the date written herein above ("EFFECTIVE                  DATE") subject to approval of                  BOARD. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**II.**
**DEFINITIONS**

| **2.1** | AFFILIATE                  means any business entity at least 50% owned by LICENSEE, any business                  entity which owns at least 50% of LICENSEE, or any business entity                  that is                  at least 50% owned by a business entity that owns at least 50%                  of                  LICENSEE. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.2** | LICENSED                  FIELD means cancer therapy. |
|---------|-------------------------------------------------------|

| **2.3** | LICENSED                  PRODUCTS means any product or service SOLD by LICENSEE or SUBLICENSEE                  comprising LICENSED SUBJECT MATTER pursuant to this                  AGREEMENT. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.4** | LICENSED                  SUBJECT MATTER means inventions and discoveries covered by PATENT                  RIGHTS                  or TECHNOLOGY RIGHTS within licensed                  Field. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.5** | LICENSED                  TERRITORY means worldwide. |
|---------|------------------------------------------------------|

----

| **2.6**  | NET                  SALES means the gross revenues received by LICENSEE or SUBLICENSEE                  from                  the SALE of LICENSED PRODUCTS less sales, discounts actually granted,                  sales and/or use taxes actually paid, import and/or export duties                  actually                  paid, outbound transportation actually prepaid or allowed, and                  amounts                  actually allowed or credited due to returns (not exceeding the                  original                  billing or invoice amount). |
|---------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.7** | PATENT                  RIGHTS means BOARD'S rights in information or discoveries covered                  in                  patents, whether domestic or foreign, and all divisionals, continuations,                  continuations-in-part, reissues, reexaminations or extensions thereof,                  any                  patent document claiming priority therefrom, and any letters patent                  that                  issue thereon as defined in Exhibit I attached                  hereto. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.8** | SALE,                  SELL or SOLD shall mean the transfer or disposition of a LICENSED                  PRODUCT                  for value to a party other than LICENSEE, SUBLICENSEE, or                  AFFILIATE. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **2.9** | TECHNOLOGY                  RIGHTS shall mean BOARD'S rights in any technical information,                  know-how,                  processes, procedures, compositions, devices, methods, formulae,                  protocols, techniques, software, designs, drawings or data created                  by the                  inventor(s) listed in Exhibit I at MDA before the Effective Date                  relating                  to the use of liposomal vinca alkaloids which are not covered by                  PATENT                  RIGHTS but which are necessary for practicing the inventions covered                  PATENT RIGHTS. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**III.**
**LICENSE**

| **3.1** | BOARD,                  through MDA, hereby grants to LICENSEE a royalty-bearing, exclusive                  license under LICENSED SUBJECT MATTER to manufacture, have manufactured,                  use and/or SELL LICENSED PRODUCTS within LICENSED TERRITORY for                  use within                  LICENSED FIELD and, subject to Paragraph 4.7 herein, will extend                  to                  BOARD's undivided interest in any LICENSED SUBJECT MATTER developed                  during                  the term of this AGREEMENT and jointly owned by BOARD and LICENSEE.                  This                  grant shall be subject to Paragraph 14.2 and 14.3 hereinbelow,                  the payment                  by LICENSEE to BOARD of all consideration as provided herein, the                  timely                  payment of all amounts due under any Sponsored Research Agreement                  between                  MDA and LICENSEE in effect during this AGREEMENT and is further                  subject to                  the following rights retained by BOARD and MDA                  to: |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(a)** | Publish                  the general scientific findings from research related to LICENSED                  SUBJECT                  MATTER and |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(b)** | Use                  LICENSED SUBJECT MATTER for educationally-related research, teaching,                  patient care, and other purposes. |
|--------|---------|-----------------------------------------------------------------------------------------------------------------------------------------------|

| **3.2** | LICENSEE                  may extend the license granted herein to any AFFILIATE provided                  that the                  AFFILIATE consents in writing to be bound by this AGREEMENT to                  the same                  extent as LICENSEE. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.3** | Subject                  to the Paragraph 3.4 herein below, LICENSEE may grant sublicenses                  under                  LICENSED SUBJECT MATTER consistent with the terms of this AGREEMENT                  provided that LICENSEE is responsible for its sublicensees relevant                  to                  this AGREEMENT, and for diligently collecting all amounts                  due LICENSEE from sublicensees. If a sublicensee pursuant hereto                  becomes                  bankrupt, insolvent or is placed in the hands of a receiver or                  trustee,                  LICENSEE, to the extent allowed under applicable law and in a timely                  manner, agrees to use its best reasonable efforts to collect all                  consideration owed to LICENSEE and to have the sublicense agreement                  confirmed or rejected by a court of proper                  jurisdiction. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **3.4** | LICENSEE                  must deliver to NIDA a true and correct copy of each sublicense                  granted by                  LICENSEE, and any modification or termination thereof, within 30                  days                  after execution, modification, or                  termination. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **3.5** | When                  this AGREEMENT is terminated, BOARD and MDA agree to accept as                  successors                  to LICENSEE, existing sublicensees in good standing at the date                  of                  termination provided that such sublicensees consent in writing                  to be bound                  by all of the terms and conditions of this                  AGREEMENT. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**IV.**
**CONSIDERATION,        PAYMENTS AND REPORTS**

| **4.1** | In                  consideration of rights granted by BOARD to LICENSEE under this                  AGREEMENT,                  LICENSEE agrees to pay MDA the                  following: |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(a)** | LICENSEE                  has been and continues to pay for expenses for future patent issues                  in                  filing, prosecuting, enforcing and maintaining PATENT RIGHTS, and                  all                  future expenses will be paid by LICENSEE, for so long as, and in                  such                  countries as, this AGREEMENT remains in effect. MDA maintains the                  option                  to file, prosecute, enforce and maintain patent rights in jurisdictions                  where LICENSEE elects to avoid patent                  prosecution. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(b)** | non-refundable                  license documentation fee in the amount of $[***]. This fee will                  not                  reduce the amount of any other payment provided for in this ARTICLE                  IV,                  and is due and payable within 30 days after the AGREEMENT has been                  fully                  executed by all parties and LICENSEE has received an invoice for                  the                  amount from MDA; |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(c)** | A                  non-refundable annual minimum license fee payable on each anniversary                  of                  the Effective Date of US $[***] prior to patent issue, and a                  non-refundable annual minimum fee of US $[***] if a patent has                  issued as                  of said anniversary date. This annual minimum fee will be invoiced                  by MDA                  and payable by LICENSEE 30 days from receipt of                  invoice. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(d)** | A                  running royalty equal to the: |
|--------|---------|--------------------------------------------------|

|   | **1)** | "Issued                  Patent" royalty designated below on the applicable portion of NET                  SALES of                  LICENSED PRODUCTS in national political jurisdictions in the LICENSED                  TERRITORY where LICENSED SUBJECT MATTER is covered by 1 or more                  issued                  patent(s) or granted/registered                  patent |
|--------|--------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **2)** | and                  a running royalty equal to the "Non-issued Patent" royalty designated                  below on the applicable portion of NET SALES of LICENSED PRODUCTS                  where                  LICENSED SUBJECT MATTER is covered by one or more pending patent                  applications but no issued or granted/registered patent as                  follows: |
|--------|--------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

**ROYALTY        SCHEDULE**

| **Royalty                  is applied to each portion of Net Sales as follows:****US                  $** |
|-----------------------------------------------------------------------------------------------------------|
|                                                                                                      | **$[***]                  - $[***]** | **$[***]                  - $[***]** | **$[***]+** |
| **Issued                  Patent**                                                                        | [***]**%** | [***]**%** | [***]**%** |
|                                                                                                      |   |   |   |
| **Royalty                  is applied to each portion of Net Sales as follows:****US                  $** |
| **Non-Issued                  Patent**                                                                    | [***]**%** | [***]**%** | [***]**%** |

**In        the event LICENSEE elected to forego patent prosecution in any given national        political jurisdiction, MDA may at its option elect to pay for and maintain        the        patent in said jurisdiction. In the absence of any other agreement between        the        parties about said jurisdiction, if Licensee has Sales in said jurisdiction,        then LICENSEE will reimburse MDA all patent expenses, 30 days after receipt        of        invoice and, in addition, LICENSEE will pay to MDA the royalty identified        in the        schedule above and an additional [***]% on Net Sales in each such jurisdiction        if the patent claims cover the Licensed Subject Matter.**

|   | **(e)** | Annual                  minimum fees paid prior to Sales will not be credited against future                  royalty payments. Any annual minimum fees made in any given year                  of Sales                  will be credited against that year's royalty                  due. |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**4.2**

| **4.3** | All                  such payments are payable within 30 days after March 31, June 30,                  September 30, and December 31 of each year during the term of this                  AGREEMENT, at which time LICENSEE will also deliver to BOARD and                  MDA a                  true and accurate report, giving such particulars of the business                  conducted by LICENSEE and its sublicensees, if any exist, during                  the                  preceding three (3) calendar months under this AGREEMENT as necessary                  for                  BOARD to account for LICENSEES's payments hereunder. This report                  will                  include pertinent data, including, but not limited                  to: |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**minimum        royalties**

| **4.4** | During                  the Term of this AGREEMENT and for 1 year thereafter, LICENSEE                  agrees to                  keep complete and accurate records of its and its sublicensees'                  SALES and                  NET SALES of LICENSED                  PRODUCTS in sufficient detail to enable the royalties payable hereunder                  to                  be determined. LICENSEE agrees to permit MDA or its representatives,                  at                  MDA's expense, to periodically, but not more than once per calendar                  year,                  examine its books, ledgers, and records during regular business                  hours for                  the purpose of and to the extent necessary to verify any report                  required                  under this AGREEMENT. If the amounts due MDA are determined to                  have been                  underpaid in an amount equal to or greater than [***]% of the total                  amount                  due during the period of time so examined, then LICENSEE will pay                  the cost                  of the examination plus the accrued interest at the highest allowable                  rate. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **4.5** | Upon                  the request of MDA, but not more than one time per calendar year,                  LICENSEE                  will deliver to MDA a written progress report as to LICENSEE'S                  (and                  sublicensees') efforts and accomplishments during the preceding                  year in                  diligently commercializing LICENSED SUBJECT MATTER in the LICENSED                  TERRITORY and LICENSEE'S (and sublicensees') commercialization                  plans for                  the upcoming year. This report is not to be construed as a performance                  obligation. |
|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **4.6** | All                  amounts payable hereunder by LICENSEE shall be payable in United                  States                  funds without deductions for taxes, assessments, fees, or charges                  of any                  kind. Checks are to be made payable to The University of Texas                  M. D.                  Anderson Cancer Center, Box 297402, Houston, Texas 77297, Attention:                  Manager, Grants and Contracts Accounting and mailed by U.S.                  mail. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **4.7** | No                  payments due or royalty rates owed under this AGREEMENT will be                  reduced as                  the result of co-ownership of LICENSED SUBJECT MATTER by BOARD                  and another                  party, including, but not limited to                  LICENSEE. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**V.**
**SPONSORED        RESEARCH**

| **5.1** | If                  LICENSEE desires to sponsor research for or related to the LICENSED                  SUBJECT MATTER, and particularly where LICENSEE receives payments                  for                  sponsored research pursuant to a sublicense under this AGREEMENT,                  LICENSEE                  will give good faith consideration to funding the proposals at                  MDA. |
|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VI.**
**PATENTS        AND INVENTIONS**

| **6.1** | If                  after consultation with LICENSEE, both parties agree that a patent                  application should be filed for LICENSED SUBJECT MATTER, BOARD                  or LICENSEE                  will prepare and file the appropriate patent applications, and                  LICENSEE                  will pay the cost of searching, preparing, filing, prosecuting                  and                  maintaining same. If LICENSEE notifies MDA that it does not intend                  to pay                  the cost of a patent application or the prosecution or maintenance                  thereof                  in a national political jurisdiction, then MDA may file, prosecute                  or                  maintain such application, at its own expense, and LICENSEE will                  have no                  further rights to such patent application or patent unless LICENSEE                  is a                  co-inventor of such, in which case right to practice the invention                  shall                  be governed by US Patent Law rules. LICENSEE will provide MDA a                  copy of                  the application for which LICENSEE has paid the cost of filing,                  as well as                  copies of any documents received or filed during prosecution                  thereof. |
|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VII.**
**INFRINGEMENT        BY THIRD PARTIES**

| **7.1** | LICENSEE,                  at its expense, has the right to enforce any patent exclusively                  licensed                  hereunder against infringement by third parties and is entitled                  to retain                  recovery from such enforcement. LICENSEE agrees to pay MDA a royalty                  on                  any monetary recovery after recovery of litigation or settlement                  expenses,                  if the monetary recovery is for damages or a reasonable royalty                  in lieu                  thereof. If LICENSEE does not file suit against a substantial infringer                  within 6 months of knowledge thereof, then BOARD and MDA may, at                  their                  sole discretion, enforce any patent licensed hereunder on behalf                  of itself                  and LICENSEE, with MDA retaining all recoveries from such enforcement,                  and/or reducing the license granted hereunder to                  non-exclusive. |
|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **7.2** | In                  any suit or dispute involving an infringer, the parties agree to                  cooperate                  fully with each other. At the request and expense of the party                  bringing                  suit, the other party will permit access to all relevant personnel,                  records, papers, information, samples, specimens, and the like,                  during                  regular business hours. |
|---------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**VIII.**
**PATENT        MARKING**

| **8.1**  | LICENSEE                  agrees that all packaging containing individual LICENSED PRODUCT(S),                  and                  documentation therefore, SOLD by LICENSEE, AFFILIATES, and/or sublicensees                  of LICENSEE will be permanently and legibly marked with the number                  of the                  applicable patent(s) licensed hereunder in accordance with each                  country's                  patent laws, including Title 35, United States                  Code. |
|---------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**IX.**
**INDEMNIFICATION**

| **9.1** | LICENSEE                  agrees to hold harmless and indemnify BOARD, SYSTEM, MDA, its Regents,                  officers, employees, students, and agents (collectively the "INDEMNITEES")                  from and against any claims, demands, or causes of action whatsoever,                  costs of suit and reasonable attorney's fees, including without                  limitation, those costs arising on account of any injury or death                  of                  persons or damage to property caused by, or arising out of, or                  resulting                  from, the exercise or practice of the license granted hereunder                  by                  LICENSEE, officers, its AFFILIATES or their officers, employees,                  agents or                  representatives except in the event of gross negligence on the                  part of any                  of the INDEMNITEES. This provision does not apply to any action                  or                  omission of any of the INDEMNITEES which is subject to another                  agreement                  between the parties or their agents, such as a sponsored research                  agreement or a clinical trial                  agreement. |
|---------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**X.**
**USE        OF BOARD AND COMPONENT'S NAME**

| **10.1** | LICENSEE                  will not use the name of (or the name of any employee of) MDA,                  SYSTEM or                  BOARD without the advance express written consent of BOARD secured                  through: |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XI.**
**CONFIDENTIAL        INFORMATION AND PUBLICATION**

| **11.1** | MDA                  and LICENSEE each agree that all information contained in documents                  marked                  "confidential" and forwarded to one by the other (1) are to be                  received in                  strict confidence, (ii) used only for the purposes of this AGREEMENT,                  and                  (iii) not disclosed by the recipient party (except as required                  by law or                  court order), its agents or employees without the prior written                  consent of                  the other party, except to the extent that the recipient party                  can                  establish competent written proof that such                  information: |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **11.2** | Each                  party's obligation of confidence hereunder will be fulfilled by                  using at                  least the same degree of care with the other party's confidential                  information as it uses to protect its own confidential information.                  This                  obligation will exist while this AGREEMENT is in force and for                  a period of                  3 years thereafter. |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **11.3** | MDA                  reserves the right to publish the general scientific findings from                  research related to LICENSED SUBJECT MATTER, with due regard to                  the                  protection of LICENSEE'S confidential information. MDA will submit                  the                  manuscript of any proposed publication to LICENSEE at least 30                  days before                  publication, and LICENSEE shall have the right to review and comment                  upon                  the publication in order to protect LICENSEE'S confidential information.                  Upon LICENSEE'S request, publication may be delayed up to 60 additional                  days to enable LICENSEE to secure adequate intellectual property                  protection of LICENSEE'S confidential information that would be                  affected                  by the publication. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XII.**
**ASSIGNMENT**

| **12.1** | Except                  in connection with the sale of substantially all of LICENSEE's                  assets to a                  third party, this AGREEMENT may not be assigned by LICENSEE without                  the                  prior written consent of BOARD, which will not be unreasonably                  withheld. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XIII.**
**TERM        AND TERMINATION**

| **13.1** | Subject                  to Articles 13.2, 13.3 and 13.4 hereinbelow, the term of this AGREEMENT                  is                  from the EFFECTIVE DATE to the full end of the term or terms for                  which                  PATENT RIGHTS have not expired, or if only TECHNOLOGY RIGHTS are                  licensed                  and no PATENT RIGHTS are applicable, for a term of 15                  years. |
|----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **13.2** | Any                  time after 1 year from the EFFECTIVE DATE, BOARD and MDA have the                  right to                  terminate this license in any national political jurisdiction within                  the                  LICENSED TERRITORY if LICENSEE, within 90 days after receiving                  written                  notice from MDA of the intended termination, fails to provide written                  evidence satisfactory to MDA that LICENSEE or its sublicensee(s)                  has                  commercialized or is actively attempting to commercialize a licensed                  invention in such jurisdiction(s). The following definitions apply                  to                  Section 13.2: (i) "commercialize" means having SALES of LICENSED                  PRODUCTS                  incorporating PATENT RIGHTS or incorporating TECHNOLOGY RIGHTS                  in such                  jurisdiction; or (ii) “active attempts to commercialize” means ongoing and                  active research, development, manufacturing, marketing, or sales                  program                  as appropriate, directed toward obtaining regulatory approval,                  and/or                  production and/or SALES of LICENSED PRODUCTS incorporating PATENT                  RIGHTS                  or incorporating TECHNOLOGY RIGHTS in any jurisdiction, and has                  provided                  plans acceptable to MDA, in its sole discretion, to commercialize                  licensed                  inventions in the jurisdiction(s) that MDA intends to terminate.                  Parties                  acknowledge that to the extent LICENSEE is a joint owner of Patent                  Rights,                  such termination does not inhibit LICENSEE's right to practice                  under its                  undivided interest in the                  invention. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **13.3** | Subject                  to any rights herein which survive termination, this AGREEMENT                  will                  earlier terminate in its entirety: |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(a)** | automatically                  if LICENSEE shall become bankrupt or insolvent and/or if the business                  of                  LICENSEE shall be placed in the hands of a receiver or trustee,                  whether by                  voluntary act of LICENSEE or otherwise;                  or |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(b)** | upon                  30 days written notice by MDA if LICENSEE breaches or defaults                  on the                  payment or report obligations of ARTICLE IV, or use of name obligations                  of                  ARTICLE X; unless, before the end of the 30 day period, LICENSEE                  has cured                  the default or breach and so notifies BOARD, stating the manner                  of the                  cure; or |
|--------|---------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(c)** | upon                  90 days written notice from MDA if LICENSEE breaches or defaults                  on any                  other obligation under this AGREEMENT (such written notice to specify                  such                  breach or default), unless, before the end of the 90 day period,                  LICENSEE                  has cured the default or breach and so notifies BOARD, stating                  the manner                  of the cure; or |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(d)** | at                  any time by mutual written agreement between LICENSEE, MDA and                  BOARD, upon                  130 days written notice to all parties and subject to any terms                  herein                  which survive termination; or |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(e)** | in                  relevant part under the provisions of Paragraph 13.2 if                  invoked. |
|--------|---------|-------------------------------------------------------------------------------------------------------|

**13.4**

|   | **(a)** | nothing                  herein shall be construed to release either party of any obligation                  matured prior to the effective date of the                  termination; |
|--------|---------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(b)** | LICENSEE                  covenants and agrees to be bound by the provisions of ARTICLES                  IX                  (indemnification), X (Use of Board and Component's Name) and XI                  (Confidential Information) of this                  AGREEMENT; |
|--------|---------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|   | **(c)** | LICENSEE                  may, after the effective date of such termination, SELL all LICENSED                  PRODUCTS that it has on hand at the date of termination, if LICENSEE                  pays                  the earned royalty thereon and any other amounts due pursuant to                  ARTICLE                  IV of this AGREEMENT. |
|--------|---------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XIV.**
**WARRANTY:        SUPERIOR-RIGHTS**

| **14.1** | Except                  for the rights, if any, of the Government of the United States                  as set                  forth below, BOARD represents and warrants its belief that (1)                  it is the                  owner of an undivided joint right, title, and interest in and to                  LICENSED                  SUBJECT MATTER, (2) it has the right to grant an exclusive license                  to its                  rights, title and interest thereunder, and (3) it has not knowingly                  granted licenses thereunder to any other entity that would restrict                  rights                  granted hereunder except as stated                  herein. |
|----------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

----

| **14.2** | LICENSEE                  understands that the LICENSED SUBJECT MATTER may have been developed                  under                  a funding agreement with the Government of the United States of                  America                  and, if so, that the Government may have certain rights relative                  thereto.                  This AGREEMENT is explicitly made subject to the Governments rights                  under                  any such agreement and any applicable law or regulation, including                  P.L.                  96-517 as amended by P.L. 98-620. To the extent that there is a                  conflict                  between any such agreement, applicable law or regulation and this                  AGREEMENT, the terms of such Government agreement, applicable law                  or                  regulation shall prevail. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **14.3** | LICENSEE                  understands and agrees that BOARD, by this AGREEMENT, makes no                  representation as to the operability or fitness for any use, safety,                  and                  efficacy, approvability by regulatory authorities, time and cost                  of                  development, patentability, and/or breadth of the LICENSED SUBJECT                  MATTER.                  BOARD, by this AGREEMENT, also makes no representation as to whether                  there                  are any patents now held, or which will be held, by others or by                  BOARD in                  the LICENSED FIELD, nor does BOARD make any representation that                  the                  inventions contained in PATENT RIGHTS do not infringe any other                  patents                  now held or that will be held by others or by                  BOARD. |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **14.4** | LICENSEE,                  by execution hereof, acknowledges, covenants and agrees that LICENSEE                  has                  not been induced in anyway by BOARD, SYSTEM, MDA or employees thereof                  to                  enter into this Agreement, and further warrants and represents                  that (i)                  LICENSEE has conducted sufficient due diligence with respect to                  all items                  and issues pertaining to this Agreement; and (ii) LICENSEE has                  adequate                  knowledge and expertise, or has used knowledgeable and expert consultants,                  to adequately conduct such due diligence, and agrees to accept                  all risks                  inherent herein. |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**XV.**
**GENERAL**

| **15.1** | This                  AGREEMENT constitutes the entire and only AGREEMENT between the                  parties                  for LICENSED SUBJECT MATTER and all other prior negotiations,                  representations, agreements and understandings are superseded hereby.                  No                  agreements altering or supplementing the terms hereof may be made                  except                  by a written document signed by both                  parties. |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.2** | Any                  notice required by this AGREEMENT shall be given by prepaid, first                  class,                  certified mail, return receipt requested, and addressed in the                  case of                  BOARD to: |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

|                          | BOARD                  OF REGENTSThe                  University of Texas System201                  West Seventh StreetAustin,                  Texas 78701ATTENTION:                  Office of General Counsel                                                         |
|-------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
|                          |                                                                                                                                                                                                                                                                      |
| With                  copy to | The                  University of TexasM.D.                  Anderson Cancer CenterOffice                  of Technology Development1020                  Holcombe Boulevard, Suite 1405Houston,                  Texas 77030ATTENTION:                  William J. Doty |

----

| Or                  in the case of LICENSEE to: | President                  and CEOATTN:                  Mr. David J. MainINEX                  Pharmaceuticals Corporation100-8900                  Glenlyon PkwyBurnaby                  BCCANADA                  V5J5J8 |
|-------------------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.3** | LICENSEE                  must comply with all applicable federal, state and local laws and                  regulations in connection with its activities pursuant to this                  AGREEMENT. |
|----------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.4** | This                  AGREEMENT shall be construed and enforced in accordance with the                  laws of                  the United States of America and of the State of                  Texas. |
|----------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.5** | Failure                  of BOARD to enforce a right under this AGREEMENT will not act as                  a waiver                  of that right or the ability to later assert that right relative                  to the                  particular situation involved. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.6** | Headings                  included herein are for convenience only and shall not be used                  to construe                  this AGREEMENT. |
|----------|--------------------------------------------------------------------------------------------------------------------------------------------------------|

| **15.7** | If                  any part of this AGREEMENT is for any reason to be found unenforceable,                  all other parts nevertheless will remain                  enforceable. |
|----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**IN        WITNESS WHEREOF, parties hereto have caused their duly authorized        representatives to execute this AGREEMENT.**

| THE                  UNIVERSITY OF TEXASM.D.                  ANDERSON CANCER CENTER                                                                                       | BOARD                  OF REGENTS OF THEUNIVERSITY                  OF TEXAS SYSTEM                                                             |
|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                                                       |                                                                                                                                            |
|                                                                                                                                                                       |                                                                                                                                            |
| By                   /s/                  Michael J. Best                                                                                              | By                   /s/                  John Mendelsohn, M.D.                                                                  |
|                                                                                                                                                                       |                                                                                                                                            |
| Michael                  J. BestAssociate                  Vice PresidentFor                  Business AffairsDate:                  1-24-00      | John                  Mendelsohn, M.D.President,                  M.D. Anderson CancerCenterDate:                  2-9-00             |
|                                                                                                                                                                       |                                                                                                                                            |
| APPROVED                  AS TO CONTENT:                                                                                                                                   | APPROVED                  AS TO FORM:                                                                                                           |
|                                                                                                                                                                       |                                                                                                                                            |
|                                                                                                                                                                       |                                                                                                                                            |
| By                   /s/                  William J. Doty                                                                                              | By                   /s/                  BethLynn Maxwell                                                                       |
|                                                                                                                                                                       |                                                                                                                                            |
| William                  J. DotyDirector,                  Technology DevelopmentDate:                  01/20/2000                                               | BethLynn                  Maxwell, Esq.Office                  of General CounselDate:                  14                  Feb. 00   |

----

| INEX                  PHARMACEUTICALS CORPORATION                                                                                                |
|--------------------------------------------------------------------------------------------------------------------------------------------------|
|                                                                                                                                             |
|                                                                                                                                             |
| By                   /s/                  David J. Main                                                                      |   |
|                                                                                                                                             |   |
| Name:                  David J. MainTitle:                  President & CEODate:                  June                  14, 2000   |   |

----

**EXHIBIT        I**

----